{
    "nctId": "NCT01621425",
    "briefTitle": "Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity",
    "officialTitle": "Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Castration-resistant Prostate Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "anthropometric parameters related to exposure",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject is at least 18\n* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations\n* Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol (TAC regimen) or male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol (PRODOC regimen)\n* Subject has a live expectancy of 12 weeks or greater\n* Absolute neutrophile count (ANC) \\> 1.5 x 10E9/L\n* Platelet count \\> 100 x 10E9/L\n* Serum creatinine \u2264 2 x ULN\n* Total bilirubin level \\< 1.5 x ULN\n\nExclusion Criteria:\n\n* Docetaxel treatment within the last year\n* Moderate or severe liver impairment; \\[ALAT and/or ASAT \u2265 1.5 ULN\\] and \\[AF \u2265 2.5 ULN\\]\n* Current therapy with any drug, dietary supplements, or other compounds, or have been used in the last 2 weeks prior to the first docetaxel administration, known to inhibit or induce CYP3A4.\n* Inability to understand the nature and extent of the study and the procedures required",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}